TimeScale Financial’s Arbutus Biopharma ABUS Stock Holding History

TimeScale Financial’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$690	Hold	300	–	–	﹤0.01%	560
2023 Q1	$909	Hold	300	–	–	﹤0.01%	539
2022 Q4	$573	Hold	300	–	–	﹤0.01%	532
2022 Q3	$1K	Hold	300	–	–	﹤0.01%	478
2022 Q2	$1K	Hold	300	–	–	﹤0.01%	447
2022 Q1	$1K	Hold	300	–	–	﹤0.01%	469
2021 Q4	$1K	Hold	300	–	–	﹤0.01%	465
2021 Q3	$1K	Hold	300	–	–	﹤0.01%	456
2021 Q2	$1K	Hold	300	–	–	﹤0.01%	457
2021 Q1	$1K	Hold	300	–	–	﹤0.01%	451
2020 Q4	$1K	Hold	300	–	–	﹤0.01%	391
2020 Q3	$1K	Hold	300	–	–	﹤0.01%	413
2020 Q2	$1K	Hold	300	–	–	﹤0.01%	405
2020 Q1	$0	Hold	300	–	–	﹤0.01%	404
2019 Q4	$0	Hold	300	–	–	﹤0.01%	503
2019 Q3	$0	Hold	300	–	–	﹤0.01%	494
2019 Q2	$1K	Buy	+300	New	+$767	﹤0.01%	467

Other funds holding ABUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return